This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEDAF0IH_M.jpg
Key takeaways from the call include:
Palatin (NYSE:PTN) is also developing a novel formulation for men with erectile dysfunction who have failed current treatments. The company highlighted the large market opportunity for this underserved population and plans to initiate clinical programs by the end of the year. Furthermore, they’re making progress in ocular programs, specifically MELODY-1, and have presented positive data for PL9643, a potential treatment for dry eye disease.
The CEO of Palatin discussed the potential for a new product in the erectile dysfunction (ED) space, expressing belief in a low clinical risk and high medical need for this product. The company has conducted studies on a combination of their drug bremelanotide with PDE-5 inhibitors, showing promising results. They have also had discussions with third parties interested in distributing the product.
In addition, the company is interested in the obesity space and has conducted studies on bremelanotide for weight loss in obese patients. They have expertise in the melanocortin system, a target for obesity treatment. The company is considering longer-term plans for their product Vyleesi, potentially marketing it as a treatment for both male and female sexual dysfunction. They are also exploring opportunities in other therapeutic areas, such as dry eye disease and glaucoma.
Palatin also expressed excitement about their melanocortin mechanism and the potential for their products to protect the back of the eye from damage. They emphasized the need for products that can lower intraocular pressure and provide nerve protection. The company is looking for a partnership for PL9643 and plans to prioritize resources accordingly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
